SPOTLIGHT -
Rising Temperatures Detrimental to Renal Function in Heart Failure Outpatients
Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.
Fish Oil Supplement Intake Influences Long-Term Atrial Fibrillation Risk
Increased risk of AF by fish oil supplement was found to be prominent in low risk participants with healthy lifestyles.
Full-Dose Anticoagulation Lowers Thrombotic Event Risk in Patients with COVID-19
Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19.
Atrial Fibrillation Screening Using Smartphones Significantly Increases Detection Rate
Digital screening more than doubled the detection rate of treatment-relevant AF in both phases of eBRAVE-AF trial.
SGLT2 Inhibitor Therapy Foundational in Wide Range of Heart Failure Management
SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention
The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.
Suboptimal Sleep Linked to Greater Likelihood of Heart Disease
The risk of coronary heart disease and stroke decreased by 22% for every 1 point rise in the sleep score at baseline.
Influenza Vaccination After Myocardial Infarction Lowers Risk of Future CV Events
Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.
Bertram Pitt, MD: Treating Diabetes, CKD Aggressively with Finerenone
Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.
Hypertension Fixed-Dose Quadpill Treatment Linked to Decrease in Blood Pressure
Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.
Fixed-Dose Combination Treatments Show Increased Reduction of CVD Outcomes
Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.
Intensive Treatment Leads to Lower CV Events In Older Patients with Hypertension
Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.
Implantable Loop Recorder Increases AFib Detection in Patients At Risk of Stroke
Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.
Deepak Bhatt, MD: Utility of Icosapent Ethyl in At-Risk Patient Populations
Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.
Pharmacological Blood Pressure Reduction Effective in All Age Groups
Despite conflicting evidence surrounding older patient populations, investigators found no age-specific treatment effects on major cardiovascular outcomes.
Deepak Bhatt, MD: Icosapent Ethyl Use in Patients with Prior Myocardial Infarction
Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.
Salt Substitute Reduces Risks of Cardiovascular Events
Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.
Immediate Angiography Not Preferred Over Delayed or Selective Strategies
A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.
Finerenone Improves CV Outcomes in Patients with T2D, CKD in FIGARO-DKD Study
Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).
Single Month of Dual Antiplatelet Therapy Noninferior to Continued Therapy After PCI
Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.
Edoxaban Non-Inferior to Vitamin K Antagonist for Post-TAVR Atrial Fibrillation
The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.
Empagliflozin Reduces Hospitalizations, Deaths in HFpEF Patients
New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.
New Targeted Inhibitor Offers Promise for Patients with Symptomatic Obstructive HCM
Current therapies focus on relief of symptoms, but there is still an unmet need to address and target the molecular defects of hypertrophic cardiomyopathy.
The COVID-19 and Cardiovascular Risk Intersection: 3 Major Considerations
Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.
Empagliflozin Improves CV Outcomes in Patients with Obstructive Sleep Apnea
Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.
Evolocumab Helps Type 2 Diabetes Patients Reach Lipid Level Goals
These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.
New Lifetime Risk Equation More Accurately Predicts CV Risk and Treatment Benefits
The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.
HDL-C Not Determinant in Improved CAD Treatment
Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.
ESC 2020 Takeaways
The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.
BMI Strongly Predicts Individual Risk for Diabetes
New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.